Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
Sponsor: M.D. Anderson Cancer Center
Summary
This trial studies the effect of pegloticase in reducing uric acid levels in patients with hyperuricemia (high blood levels of uric acid) caused by tumor lysis syndrome. Tumor lysis syndrome occurs when the breakdown products of cancer cells, such as uric acid, enter the blood stream. High levels of uric acid in blood may cause kidney damage and reduce kidney function. The goal of this trial is to learn if pegloticase may lower uric acid levels in blood when given to cancer patients with hyperuricemia caused by tumor lysis syndrome.
Official title: Effect of Pegloticase on Reduction of Uric Acid in Patients With Tumor Lysis Syndrome: A Pilot Pragmatic Clinical Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2022-04-05
Completion Date
2026-07-31
Last Updated
2025-12-18
Healthy Volunteers
No
Interventions
Pegloticase
Given IV
Rasburicase
Given IV
Locations (1)
M D Anderson Cancer Center
Houston, Texas, United States